Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Details

Language :

English

ISSN :

07423071

Volume :

26

Issue :

3

Database :

Complementary Index

Journal :

Diabetic Medicine

Publication Type :

Academic Journal

Accession number :

105483214

Full Text :

https://doi.org/10.1111/j.1464-5491.2009.02666.x